MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$77,359K
EPS
-$0.71
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
Research and development
41,484 29,416*
General and administrative
17,736 12,161*
Total operating expenses
59,220 41,577
Loss from operations
-59,220 -41,577*
Interest income
3,457 2,740*
Interest expense
1,245 1,371*
Foreign exchange loss, net
-44 -33*
Change in fair value of 2022 usd financing warrants
20,046 5,708*
Gain on extinguishment of contribution payable
-0*
Total other income/(expense)
-17,878 -4,371*
Net loss
-77,098 -45,948*
Unrealized gain/(loss) on investments
-262 83*
Gain/(loss) on foreign currency translation
1 -16*
Comprehensive loss
-77,359 -45,882
Basic EPS
-0.71 -0.514
Diluted EPS
-0.71 -0.514
Basic Average Shares
108,790,941 89,327,608
Diluted Average Shares
108,790,941 89,327,608
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Comprehensive loss-$77,359K Gain/(loss) on foreigncurrency translation$1K Net loss-$77,098K Unrealized gain/(loss) oninvestments-$262K Loss from operations-$59,220K Total otherincome/(expense)-$17,878K Interest income$3,457K Total operatingexpenses$59,220K Change in fair value of2022 usd financing...$20,046K Interest expense$1,245K Foreign exchange loss,net-$44K Research and development$41,484K General andadministrative$17,736K

Definium Therapeutics, Inc. (DFTX)

Definium Therapeutics, Inc. (DFTX)